Pamela Vig, Ph.D., is chief scientific officer for Mirum Pharmaceuticals, where she leads scientific and clinical aspects of drug development.
Pam brings 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including HBV, HCV, NASH and cholestatic liver disease, as well as HIV and other infectious diseases. Most recently, she has held leadership roles at Allergan and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions at Idenix Pharmaceuticals and Gilead Sciences.
Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.